Moderna announces advances across mRNA pipeline
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students
The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare
To create leading company developing medicines targeting metalloenzymes
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.
Cipla and Ethris partner for the development of mRNA-based therapies
The cash and debt free consideration value is €370 million.
Subscribe To Our Newsletter & Stay Updated